Publications

2010
141. Four-and-a-half LIM domain protein 2 is a novel regulator of sphingosine 1-phosphate receptor 1 in CCL19-induced dendritic cell migration.
König K, Diehl L, Rommerscheidt-Fuss U, Golletz C, Quast T, Kahl P, Kolanus W, Knolle P, Buettner R, Heukamp LC
J Immunol. 2010 Aug 1.
PMID: 20592280 [PubMed - in process]
142. Biophysical characterization of copolymer-protected gene vectors.
Hönig D, DeRouchey J, Jungmann R, Koch C, Plank C, Rädler JO
Biomacromolecules. 2010 Jul 12.
PMID: 20672861 [PubMed - in process]
143. Tetracycline-regulated bone morphogenetic protein 2 gene expression in lentivirally transduced primary rabbit chondrocytes for treatment of cartilage defects.
Wübbenhorst D, Dumler K, Wagner B, Wexel G, Imhoff A, Gansbacher B, Vogt S, Anton M
Arthritis Rheum. 2010 Jul .
PMID: 20309869 [PubMed - in process]
144. Cross-priming in health and disease.
Kurts C, Robinson BW, Knolle PA
Nat Rev Immunol. 2010 Jun .
PMID: 20498667 [PubMed - in process]
145. Immunotherapy of hepatocellular carcinoma.
Korangy F, Höchst B, Manns MP, Greten TF
Expert Rev Gastroenterol Hepatol. 2010 Jun .
PMID: 20528121 [PubMed - in process]
146. Immune responses in hepatocellular carcinoma.
Korangy F, Höchst B, Manns MP, Greten TF
Dig Dis. 2010 .
PMID: 20460904 [PubMed - in process]
147. Bioluminescence imaging allows measuring CD8 T cell function in the liver.
Stabenow D, Frings M, Trück C, Gärtner K, Förster I, Kurts C, Tüting T, Odenthal M, Dienes HP, Cederbrant K, Protzer U, Knolle PA
Hepatology. 2010 Apr .
PMID: 20373369 [PubMed - in process]
148. Methods to monitor distribution and metabolic activity of mesenchymal stem cells following in vivo injection into nucleotomized porcine intervertebral discs.
Omlor GW, Bertram H, Kleinschmidt K, Fischer J, Brohm K, Guehring T, Anton M, Richter W
Eur Spine J. 2010 Apr .
PMID: 20039083 [PubMed - in process]
149. Steady-state cross-presentation of OVA is mannose receptor-dependent but inhibitable by collagen fragments.
Burgdorf S, Schuette V, Semmling V, Hochheiser K, Lukacs-Kornek V, Knolle PA, Kurts C
Proc Natl Acad Sci U S A. 2010 Mar 30.
PMID: 20308535 [PubMed - in process]
150. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC.
Greten TF, Ormandy LA, Fikuart A, Höchst B, Henschen S, Hörning M, Manns MP, Korangy F
J Immunother. .
PMID: 20139774 [PubMed - in process]